Timothy Voorhees, MD, MSCR
@tvoorheesmd
Followers
417
Following
1K
Statuses
186
Assistant Professor @OSUCCC_James | #Lymphoma | Previously @UNC_Lineberger & @OSUWexMed | Proud Dad/Husband | Tweets & Opinions Are My Own, Not Medical Advice
Columbus, OH
Joined September 2009
RT @majorajay: Analysis of R maint problem in TRIANGLE #ASH24: 4-yr PFS with R maint vs not (not randomized): - I: 86% vs 76% - A+I: 89% vs…
0
5
0
RT @majorajay: 5-yr f/u ZUMA-5 (axi-cel in iNHL) #ASH24: - 159 pts (most FL) with 2+ LOT - mPFS 62 mo! (FL 57 mo, MZL NR) - however, mPFS 7…
0
4
0
RT @tobyeyre82: Salles et al 5 yr results of POLARIX 1L RCT PolaRCHP vs RCHOP in IPI 2-5 DLBCL 5-year PFS estimates 64.2% vs 59.1% HR 0.7…
0
26
0
RT @AaronGoodman33: ABIM has eliminated 2 year MOC points! In case not everyone is an avid reader of the ABIM blog I provided a link Hope…
0
45
0
RT @mlieducation: 🚨CME ALERT🚨Our #SOHO2024 symposium on EBV+ PTLD is now available On Demand! Hear expert insights from @MahadeoKris & @tv…
0
2
0
RT @OSUHematology: Heme Sweeps the @OSUCCC_James Physician Recognition Celebration! 🏆 Heme Faculty earned: ✔️Physician of the Year (@mmosu…
0
1
0
Getting excited for @Pelotonia 2024! Riding 50 miles this year, 100% of every dollar raised funds innovative research @OSUCCC_James. Please consider supporting my ride!
0
1
10
RT @ChadPecot: 7 years ago we started a grant workshop for the fellows @UNC_Lineberger @UNC We've received 20 YIA awards @ASCO @ConquerCa…
0
6
0
RT @Pelotonia: Over 4,000 Riders have registered for Pelotonia 2024! 🚀 Your momentum has continued to soar since registration opened two m…
0
4
0
Nice data and approach for CNS prophylaxis with primary testicular DLBCL ⭐️ separates HDMTX from chemotherapy ⭐️ MTX 1.5g/m2 x 2 cycles ⭐️ contralateral RT ⭐️ no CNS relapse at median follow up of 6 years
Combined intravenous and intrathecal prophylaxis is feasible and effective in preventing central nervous system relapses, improving outcome. #lymphoidneoplasia #clinicaltrialsandobservations
0
0
3
@nico30f @laura_korin @majorajay @DrRaulCordoba @GuiperiniMD @PallawiTorkaMD @Ali_von @Eddie_Cliff I’ve used this data to justify no further dose escalation or even DL reduction if a pt experiences significant non hematologic toxicity. However, if a pt is doing well and hasn’t had a nadir, I still dose escalate regardless of the prior DL.
0
0
0
Registered for @Pelotonia 2024. Who's riding with me? @OSUCCC_James @OSUHematology
#lymphoma #OneGoal #lymsm
2
1
8
Congratulations @kmaddmd - well deserved!
Dr. Maddocks (@kmaddmd) is now a member of the Executive Committee, for the Mantle Cell @lymphoma Consortium (MCLC). Her expertise will be identifying gaps in research & patient care for this historically understudied patient population.👏 @OSUCCC_James
0
0
8
Proud to see @OSUHematology @OSUCCC_James Heme/Onc fellow Amneet Bajwa, MD present our work showing benefit of Siltuximab for refractory CRS/ICANS after #CART cell therapy! #ASH23
0
4
25
Very interesting data for pre-emptive Rituximab for EBV viremia after solid organ transplant! @ASH23
Impressive data from our first year fellow @ev_lando showing the impact of preemptive rituximab in prevention of PTLD in solid organ transplant recipients. Very large sample! @jenamengual
0
0
4
RT @RemyDulery: #ASH23 Abstract 900 by @tvoorheesmd et al. Real world data indicating that allogeneic HCT and CD30 #CARTcell were highly…
0
3
0
5/5 📌#ASH23 [Top Hodgkin lymphoma abstracts] Abstract 900 by @tvoorheesmd et al. Allogeneic HCT and CD30 CAR T-cell are associated with improved survival in Hodgkin lymphoma refractory/intolerant to brentuximab and anti-PD-1 therapy: real world data! 👉
0
1
6